Wire flash
FinanceVertex to acquire Crinetics for $85/share in cash, valuing deal at ~$10B
Editorial responsibility
- No named human review is recorded for this page.
- Source reporting is collected, normalized, translated or condensed automatically when needed.
- Automatically published source-backed update
Crinetics Pharmaceuticals (CRNX) is highlighted as a potential buying opportunity after a 44% stock decline since mid-January 2026. UBS analyst Ashwani Verma initiated coverage with a Buy rating and $55 price target, citing strong pipeline catalysts including the Phase 3 atumelnant program for congenital adrenal hyperplasia with $2 billion peak sales potential. On July 6, 2026, Vertex Pharmaceuticals announced a definitive agreement to acquire Crinetics for $85 per share in cash, valuing the company at approximately $10 billion. The deal, approved by both boards, is expected to close in Q3 2026. Crinetics focuses on oral non-peptide therapies for endocrine diseases, with approved drug PALSONIFY for acromegaly and pipeline assets for Cushing's syndrome, Graves' disease, and obesity.
Source report
Laiba Immad Wed, July 8, 2026 at 8:04 AM PDT 2 min read
- CRNX
We recently compiled a list of the 10 Best Innovative Healthcare Stocks to Buy Now. Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is one of the best healthcare stocks on our list.
Analyst Coverage and Outlook
TheFly reported on July 2 that UBS analyst Ashwani Verma initiated coverage of CRNX with a Buy rating and a $55 price target. The analyst noted that the stock's 44% decline since mid-January presents an appealing opportunity for investors.
UBS highlighted CRNX's pipeline as having multiple potential catalysts, supported by programs with strong chances of clinical success. The firm expressed the highest confidence in the Phase 3 atumelnant program for congenital adrenal hyperplasia and projects peak sales potential of approximately $2.0 billion.
Acquisition Announcement
On July 6, Vertex Pharmaceuticals and Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) announced a definitive agreement under which Vertex will acquire Crinetics for $85.00 per share in cash, representing an equity value of approximately $10 billion, or about $8.8 billion after accounting for estimated acquired cash.
- The transaction received unanimous approval from both companies' boards.
- The acquisition is expected to close in the third quarter of 2026.
- Vertex stated that CRNX's endocrine-focused portfolio, including PALSONIFY and atumelnant, aligns with its strategy of developing transformative medicines for diseases with significant unmet needs.
- The combined assets are projected to provide more than $5 billion in potential peak annual revenue, supporting Vertex's revenue growth.
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is a clinical-stage biopharmaceutical company focused on developing oral, non-peptide therapies for endocrine diseases and tumors by targeting G-protein-coupled receptors (GPCRs). Key programs include:
- PALSONIFY (paltusotine): An FDA- and EMA-approved oral treatment for acromegaly.
- Atremelnant: A Phase 3 therapy for congenital adrenal hyperplasia and Cushing's syndrome.
- A pipeline targeting conditions such as Graves' disease, obesity, and other endocrine disorders.
These factors underpin the company's innovative profile.
Note: While we acknowledge the potential of CRNX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years
Disclosure: None. Follow Insider Monkey on Google News
View Comments
Source
Yahoo FinanceWestern
Part of this Story
Vertex acquires Crinetics for $10B to expand into rare endocrine diseases